IDH1 and cholangiocarcinoma: The phase III ClarIDHy trial assessed the efficacy of ivosidenib (500 mg orally once daily) compared with that of a placebo arm in adult patients with locally advanced or metastatic CCA harboring an IDH1 mutation following the failure of first-line therapy.